Equities research analysts expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) to report sales of $6.60 million for the current quarter, Zacks reports. Five analysts have made estimates for Aurinia Pharmaceuticals’ earnings. The lowest sales estimate is $3.70 million and the highest is $9.60 million. Aurinia Pharmaceuticals reported sales of $30,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 21,900%. The business is expected to issue its next earnings results on Tuesday, August 10th.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $59.08 million for the current year, with estimates ranging from $48.81 million to $66.60 million. For the next fiscal year, analysts forecast that the company will report sales of $216.48 million, with estimates ranging from $155.21 million to $268.67 million. Zacks’ sales averages are an average based on a survey of analysts that follow Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Wednesday, May 5th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Aurinia Pharmaceuticals had a negative net margin of 173,992.23% and a negative return on equity of 36.98%.
A number of research firms recently issued reports on AUPH. Royal Bank of Canada lowered their target price on Aurinia Pharmaceuticals from $26.00 to $23.00 and set an “outperform” rating on the stock in a research report on Friday, May 7th. HC Wainwright lifted their price target on Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, January 25th. SVB Leerink reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Sunday, April 11th. Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 27th. Finally, Bloom Burton upgraded Aurinia Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Friday, May 7th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $26.29.
Shares of NASDAQ:AUPH remained flat at $$12.82 during midday trading on Thursday. The company had a trading volume of 1,712,547 shares, compared to its average volume of 4,436,127. The company’s fifty day moving average is $12.33 and its 200 day moving average is $13.82. The firm has a market capitalization of $1.64 billion, a PE ratio of -8.72 and a beta of 0.87. Aurinia Pharmaceuticals has a twelve month low of $9.72 and a twelve month high of $20.50.
In other news, CEO Peter Greenleaf acquired 5,125 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, May 11th. The stock was bought at an average price of $10.71 per share, for a total transaction of $54,888.75. Following the completion of the acquisition, the chief executive officer now directly owns 10,461 shares in the company, valued at approximately $112,037.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jill Leversage acquired 2,500 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, May 11th. The shares were purchased at an average price of $10.96 per share, with a total value of $27,400.00. Following the acquisition, the director now owns 3,700 shares of the company’s stock, valued at $40,552. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 18,525 shares of company stock valued at $191,722.
Large investors have recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth approximately $29,000. Sowell Financial Services LLC boosted its stake in shares of Aurinia Pharmaceuticals by 72.6% in the first quarter. Sowell Financial Services LLC now owns 2,512 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 1,057 shares during the period. Private Capital Group LLC bought a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $34,000. Northern Oak Wealth Management Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $39,000. Finally, Penserra Capital Management LLC boosted its stake in shares of Aurinia Pharmaceuticals by 172.2% in the fourth quarter. Penserra Capital Management LLC now owns 2,940 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,860 shares during the period. Institutional investors own 51.21% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading: History of the Euro STOXX 50 Index
Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
